John P Cogswell

This inventor holds 20 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Cancer Immunotherapy. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John P Cogswell. Retrieved from https://idiyas.com/inventor/john-p-cogswell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 6.2

ph-index = 15

Forward Citations = 483(Granted Patents)

Location History:

Plainsboro, NJ (US) (2015)
Yardley, PA (US) (2018 - 2024)

Company Filing History:

20 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Cancer Immunotherapy

PD-1

PD-L1

LAG-3

Tumor Treatment

Antibodies

Signal Disruption

Tumor Targeting

Immune Response

Therapeutic Agents

Oncology Research

Biologics

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12686716 - CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING (2026-07-21),

2. 12624107 - CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING (2026-05-12),

3. 12590154 - CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING (2026-03-31),

4. 12049503 - Treatment of LAG-3 positive tumors (2024-07-30),

5. 11807686 - Treatment of LAG-3 positive tumors (2023-11-07),

6. 10604575 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2020-03-31),

7. 10584170 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2020-03-10),

8. 10577423 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2020-03-03),

9. 10323093 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-06-18),

10. 10323092 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-06-18),

11. 10316091 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-06-11),

12. 10316090 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-06-11),

13. 10308714 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-06-04),

14. 10266596 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-04-23),

15. 10266595 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling (2019-04-23),

Title: John P Cogswell - The Innovative Mind from Yardley

Introduction: John P Cogswell is a renowned inventor hailing from Yardley, Pennsylvania. His contributions to the field of innovation have left a lasting impact on various industries.

Latest Patents: John P Cogswell holds several patents in cutting-edge technologies related to renewable energy, sustainable agriculture, and advanced manufacturing processes.

Career Highlights: With a career spanning over two decades, John P Cogswell has worked with leading research institutions and companies to bring his inventions to life. His dedication to pushing the boundaries of what is possible has earned him recognition in the innovation community.

Collaborations: Throughout his career, John P Cogswell has collaborated with top engineers, scientists, and entrepreneurs to develop groundbreaking solutions to complex problems. His ability to work effectively in multidisciplinary teams has been key to his success.

Conclusion: John P Cogswell's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors. His impact on the world of technology and beyond is truly remarkable.

Profile summary based on public USPTO records.